well just like everyone else i did get the same pm's.. yet i have not seen any spam e-mails and have asked some people also.. i have read the web site and i like what they have.. may take alil time but they should move up.. they are also a low floater and by the pr on April 5th they have not paid any company to promote them.. so it could also mean they haven't been doing any dilution.. again its just my opinion.. also when i talked to the company about why they don't pr findings and such normally i got the feel they aren't experienced in talking to investors.. they are more focused on the research then spreading the word about them... dart will be going to check them out shortly so once he does we should get the real update from him.. i have posted some of the things they are in and working on.. if you haven't check out the site i suggest you do.
p.s also if anyone has the e-mail address for the t/a can u please e-mail or replay back to this post.
PATENTED PYRUVATE THERAPY
CV Sciences has the worldwide marketing and licensing rights for a patented process that provides a novel carioplegia solution containing pyruvate for use in cardiopulmonary bypass surgery. The surgery begins with preparation of the patient to allow surgical access to the heart. Next, the heart is arrested through application of the cariplegia solution. After the heart is stopped, a bypass mechanism is provided to a partially or wholly obstructed artery. When stopping of the heart is no longer necessary, administration of the cardioplegia solution is ceased, and a chemical or mechanical stimulus is used to induce the heart to resume beating.
Administration of the cardiplegia solution during surgery has numerous beneficial effects: 1) It protects the heart from injury resulting from ischemia; 2) the heart exhibits rapid and robust recovery. This process can also be used during valve replacement and repairs of structural defects of the heart.
=======================================================
Patented Catheters
Intra-aortic balloon therapy is used to stabilize heart function in instances of cardiac shock, before and after open-heart surgery and angioplasty and in the management of acute heart failure.
The Company has acquired the rights to develop and market four patented aortic catheters: an Enhanced Intra-Aortic Balloon Catheter (EIABC), a Removable Left Ventricular Assist Device with an Aortic Support Apparatus, a Coronary Artery Counterpulsation Device and Method, and a Piston-action Intra-Aortic Coronary Assist Device. The new catheter designs overcome the inefficiencies of existing products in the market, and are designed to be application specific, thereby delivering the optimal performance for any given clinical setting.
Domestic and International Markets
Currently, there are more than 600,000 cardiac catheterization procedures performed annually in the United States. There are more than 1 million cardiac catheterization procedures performed annually internationally. The market is expected to grow to 2 million procedures annually by 2008, with potential double-digit growth expected in for at least a decade after 2008.
=============================================
PATENTED THROMBORESISTANT COATING
CV Sciences owns the rights to a patented Thromboresistant Coating which has a variety of applications.
When blood comes in contact with any foreign material, the blood responds to this surface as it would to an injured surface of a blood vessel, and reacts by initiating the clotting process to stop what is misinterpreted as a potential site of blood loss. Anytime a medical device is introduced into the body, there is the risk of clot formation when the blood reacts to the surface as it does to injured tissue. Anticoagulants such as heparin and warfarin are employed to diminish this risk of clotting. However, these agents act systemically and can also prevent normal clotting, increasing the risk of stroke, shock and other complications. Previous attempts at coating medical devices have failed, either because they wear off; they cause other systemic effects; are too expensive; or are too complex to produce with consistent quality.
The Thromboresistant Coating Patent entails several methods by which a variety of coatings that have been shown to prevent clot formation and can be applied to a variety of plastics. This coating can be applied by dipping, spraying or painting the proprietary solution onto the surface of the device and allowing it to air dry.
By applying the coating onto any of a variety of medical devices — such as balloon catheters, tubing and pumps for dialysis machines and heart-lung pumps, heart valves and synthetic vascular grafts — the need for systemic coagulation can be eliminated, thus reducing the morbidity and mortality of the procedure to an extent never possible before.
=====================================================
Anti-Adhesion Technology
Adhesions are a form of internal scarring that results in unwanted attachment of tissues and organs to surrounding tissues or organs following trauma or virtually any surgical procedure. According to a major healthcare research organization, it is estimated that billions of dollars are spent each year in the U.S. for the treatment of post-surgical adhesions and their associated complications. The currently available products on the market are not sufficiently effective, and are difficult and very costly to use. CV Sciences is developing products that will be markedly more effective at a lower cost, and will also provide easier handling for the surgeons.
Research at the University of Central Florida
CV Sciences and the University of Central Florida have entered into an agreement to research and develop post-surgical anti-adhesion materials. The principal investigator, Dr. Kevin Belfield, chairman of the Department of Chemistry, is leading a team to further develop the most effective and efficient anti-adhesion materials. It is expected that the scope of this research will expand and broaden as the Company continues to develop this technology.
=========================================
Research
Forging the Future
Cardiovascular Sciences, Inc. (CV Sciences) has established a research and development project with the University of Central Florida. UCF and CV Sciences have entered into an agreement to further research and develop the post-surgical anti-adhesion materials.
The principal investigator, Dr. Kevin Belfield, chairman of the Department of Chemistry, is leading a team to develop the most effective and efficient anti-adhesion materials. It is expected that the scope of this research will expand and broaden as the Company continues to develop this technology.
In February, following an involved application process that included attendance at a university sponsored entrepreneurial training course, Cardiovascular Sciences, Inc. was accepted into the University of Central Florida’s Technology Incubator (UCFTI) program. Many universities and some local governments have established business "incubators." These are organizations set up to help small fledgling companies get up and running and to market. These incubator programs often provide services and facilities at very favorable rates, in order to let these companies focus on what they do best: develop their technologies to market.
The UCFTI has been one of the fastest growing such programs in the country and in 2004 was named the Technology Incubator of the Year by the National Business Incubation Association.
Three members of the Cardiovascular Sciences’ team have already moved into the UCFTI offices in the Research Park located on the UCF campus in Orlando, Fl. This allows the company to establish contacts and network with the more than 40 other small but growing firms already in the incubator program.
In addition to the office facilities and services provided, the company now has access to the UCF faculty, laboratories, library and other support organizations. Educational programs are also provided on a regular basis, often involving successful entrepreneurs willing to help others do what they have done. Also included is a network of business professionals that provide mentoring in all areas of business development including business and strategic planning, legal counsel, accounting/tax, human resources, government contracting, strategic partnerships, marketing and PR, financing, grant preparation, insurance and risk management.
News 
Market Data 
Discover 
